B6;129-Osmr^tm1.1Nat/J

Stock number: 011081
Research areas: Immunology, Inflammation and Autoimmunity Research, Research Tools

Description

These mice possess loxP sites on either side of the second exon (first coding exon) in the Osmr (oncostatin M receptor) gene. When crossed with a Cre recombinase-expressing strain, this strain is useful in eliminating tissue-specific expression of the gene. This strain may be useful in further characterization of this multifunctional cytokine.

Detailed description

These mice possess loxP sites on either side of the second exon (first coding exon) in the Osmr (oncostatin M receptor) gene. Mice that are homozygous for this floxed allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. When crossed with a Cre recombinase-expressing strain, this strain is useful in eliminating tissue-specific expression of the gene. Expression in the retina and retinal pigment epithelium (RPE) is undetectable in protein blots after crosses with a germline cre strain. This strain may be useful in further characterization of this multifunctional cytokine.

Development

The second exon (first coding exon) of the targeted gene was flanked by two LoxP sites. Adjacent to the second LoxP site is an Frt site left over after the excision of the PGK-neomycin selectable marker. This mutation was created in (129X1/SvJ x 129S1/Sv)F1- Kitl⁺-derived R1 embryonic stem (ES) cells. The strain was maintained on a mixed C57BL/6 and 129 genetic background by the donating laboratory.

Allele

Symbol: Osmr^tm1.1Nat
Name: targeted mutation 1.1, Jeremy Nathans
MGI accession ID: MGI:4438412
Generation method: Targeted
Attributes: Conditional ready (e.g. floxed); No functional change
Marker symbol: Osmr
Marker name: oncostatin M receptor
Chromosome: 15
Strain of origin: (129X1/SvJ x 129S1/Sv)F1-Kitl⁺
Molecular note: The second exon (first coding exon) of the targeted gene was flanked by two LoxP sites. Adjacent to the second LoxP site is an Frt site left over after the excision of the PGK-neomycin selectable marker.